glp-1 drug news Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford The GLP-1 drug boom has

Here the authors report that D-allulose triggers GLP-1 release in the gut and GLP-1R signaling on vagal afferents, counteracting arrhythmic overeating, obesity and diabetes.

This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient

The GLP-1 receptor assay is a powerful tool for the identification of GLP-1 receptor agonists aimed at treating obesity and type 2 diabetes

Here, the authors review the physiological roles of GLP-1, the potential renoprotective mechanisms of incretin-based therapies and the available renal outcome data from clinical trials.

In summary, GLP-1 drugs offer significant advantages for individuals with type 2 diabetes or weight management concerns

These findings underscore the potential for GLP-1 RAs to offer tailored protection against complex diabetic complications, marking an advancement in personalized medicine for managing diabetes-acute kidney disease.